A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Rituximab
DRUG: Venetoclax

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]